Update
$Atara Biotherapeutics(ATRA.US$ Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis
MT Newswires· 4 mins ago
Atara Biotherapeutics (ATRA) said Wednesday it submitted an investigational new drug application to the US Food and Drug Administration seeking approval for ATA3219 as a standalone treatment for systemic lupus erythematosus, or lupus nephritis that affects the kidneys.
ATA3219 is an allogeneic chimeric antigen receptor T-cell therapy that targets CD19 antigen present on B cells involved in autoimmune diseases, the company said.
The submission includes in vitro data on ATA3219's CD19 antigen-specific functional activity and CAR-mediated activity against B cells from SLE patients.
Shares of Atara Biotherapeutics rose 1.9% in recent trading Wednesday.![]()
MT Newswires· 4 mins ago
Atara Biotherapeutics (ATRA) said Wednesday it submitted an investigational new drug application to the US Food and Drug Administration seeking approval for ATA3219 as a standalone treatment for systemic lupus erythematosus, or lupus nephritis that affects the kidneys.
ATA3219 is an allogeneic chimeric antigen receptor T-cell therapy that targets CD19 antigen present on B cells involved in autoimmune diseases, the company said.
The submission includes in vitro data on ATA3219's CD19 antigen-specific functional activity and CAR-mediated activity against B cells from SLE patients.
Shares of Atara Biotherapeutics rose 1.9% in recent trading Wednesday.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
